HRP20201900T4 - Terapeutski i dijagnostički postupci kod raka - Google Patents
Terapeutski i dijagnostički postupci kod raka Download PDFInfo
- Publication number
- HRP20201900T4 HRP20201900T4 HRP20201900TT HRP20201900T HRP20201900T4 HR P20201900 T4 HRP20201900 T4 HR P20201900T4 HR P20201900T T HRP20201900T T HR P20201900TT HR P20201900 T HRP20201900 T HR P20201900T HR P20201900 T4 HRP20201900 T4 HR P20201900T4
- Authority
- HR
- Croatia
- Prior art keywords
- tumor
- binding antagonist
- patient
- tumor sample
- level
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G01N33/5752—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (11)
1. Antagonist vezanja PD-L1, naznačen time, što se upotrebljava u liječenju pacijenta koji pati od raka pluća ne-malih stanica, gdje je utvrđeno da uzorak tumora dobiven od pacijenta ima prepoznatljivu razinu ekspresije PD-L1 u 50 % ili više tumorskih stanica u uzorku tumora, pri čemu je antagonist vezanja PD-L1 jedno protutijelo, pri čemu je protutijelo atezolizumab, a pri čemu je razina ekspresije PD-L1 razina ekspresije proteina.
2. Antagonist vezanja PD-L1 za uporabu u skladu s patentnim zahtjevom 1, naznačen time, što uzorak tumora dobiven od pacijenta ima prepoznatljivu razinu ekspresije PD-L1 u imunološkim stanicama koje se infiltriraju u tumor i sadrže manje od 10 % uzorka.
3. Antagonist vezanja PD-L1 za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačen time, što je antagonist vezanja PD-L1 formuliran za uporabu u kombinaciji s drugim terapeutskim sredstvom, pri čemu je drugo terapeutsko sredstvo, neobvezno, odabrano iz skupine koja se sastoji od citotoksičnog sredstva, sredstva za inhibiciju rasta, sredstva za terapiju zračenjem, anti-angiogenog sredstva i njihovih kombinacija.
4. Postupak za (i) utvrđivanje vjerojatnosti da će pacijent koji boluje od raka pluća ne-malih stanica odgovoriti na liječenje koje sadrži antagonist vezanja PD-L1 ili (ii) predviđanje reakcije pacijenta koji pati od raka pluća ne-malih stanica na liječenje koje sadrži antagonist vezanja PD-L1, naznačen time, što taj postupak obuhvaća:
određivanje razine ekspresije PD-L1 u tumorskim stanicama u uzorku tumora dobivenom od pacijenta,
pri čemu prepoznatljiva razina ekspresije PD-L1 u 50 % ili više tumorskih stanica u uzorku tumora ukazuje na to da će pacijent vjerojatno odgovoriti na liječenje koje sadrži antagonist vezanja PD-L1, pri čemu je antagonist vezanja PD-L1 jedno protutijelo, pri čemu je protutijelo atezolizumab, a pri čemu je razina ekspresije PD-L1 razina ekspresije proteina.
5. Postupak za odabir terapije za pacijenta koji pati od raka pluća ne-malih stanica, naznačen time, što postupak obuhvaća:
određivanje razine ekspresije PD-L1 u tumorskim stanicama u uzorku tumora dobivenom od pacijenta, i
odabir terapije koja sadrži antagonist vezanja PD-L1 za pacijenta na temelju prepoznatljive razine ekspresije PD-L1 u 50 % ili više tumorskih stanica u uzorku tumora, pri čemu je antagonist vezanja PD-L1 jedno protutijelo, pri čemu je protutijelo atezolizumab, a pri čemu je razina ekspresije PD-L1 razina ekspresije proteina.
6. Postupak u skladu s patentnim zahtjevom 5, naznačen time, što postupak nadalje obuhvaća određivanje razine ekspresije PD-L1 u imunološkim stanicama koje se infiltriraju u tumor u uzorku tumora dobivenom od pacijenta, pri čemu uzorak tumora dobiven od pacijenta, neobvezno, ima prepoznatljivu razinu ekspresije PD-L1 u imunološkim stanicama koje se infiltriraju u tumor i obuhvaćaju manje od 10 % uzorka.
7. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili postupak u skladu s bilo kojim patentnim zahtjevom od 4 do 6, naznačen time, što:
(i) uzorak tumora dobiven od pacijenta obuhvaća populaciju fibroblasta i/ili miofibroblasta;
(ii) uzorak tumora dobiven od pacijenta sadrži stromu siromašnu stanicama i/ili kolageniziranu stromu; i/ili
(iii) uzorak tumora ima povećanu razinu ekspresije kolagena, STAT1, ili MEK u odnosu na referentni uzorak tumora.
8. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3 i 7, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 7, naznačen time, što antagonist vezanja PD-L1 inhibira vezanje PD-L1 na jedan ili više njegovih partnera za vezanje liganda, pri čemu antagonist vezanja PD-L1, neobvezno, inhibira vezanje PD-L1 na PD-1, na B7-1, ili na oba, PD-1 i B7-1.
9. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, te 7 i 8, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 8, naznačen time, što je rak pluća ne-malih stanica lokalno uznapredovali ili metastatski rak pluća ne-malih stanica.
10. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, te 7 i 8, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 9, naznačen time, što je uzorak tumora tumorski uzorak koji je fiksiran u formalinu i ukalupljen u parafinu (FFPE), arhivski uzorak tumora, uzorak svježeg tumora ili uzorak smrznutog tumora.
11. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, te 7 do 10, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 10, naznačen time, što:
(i) razina ekspresije proteina PD-L1 određuje se uporabom postupka odabranog iz skupine koja se sastoji od imunohistokemije (IHC), imunofluorescencije, protočne citometrije i Western blot-a; pri čemu se, neobvezno, razina ekspresije proteina PD-L1 otkriva uporabom anti-PD-L1 protutijela.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160561P | 2015-05-12 | 2015-05-12 | |
| US201562168700P | 2015-05-29 | 2015-05-29 | |
| PCT/US2016/032112 WO2016183326A1 (en) | 2015-05-12 | 2016-05-12 | Therapeutic and diagnostic methods for cancer |
| EP16724821.0A EP3294770B2 (en) | 2015-05-12 | 2016-05-12 | Therapeutic and diagnostic methods for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20201900T1 HRP20201900T1 (hr) | 2021-01-22 |
| HRP20201900T4 true HRP20201900T4 (hr) | 2024-06-07 |
Family
ID=56072467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201900TT HRP20201900T4 (hr) | 2015-05-12 | 2016-05-12 | Terapeutski i dijagnostički postupci kod raka |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20180030138A1 (hr) |
| EP (2) | EP3294770B2 (hr) |
| JP (3) | JP7048319B2 (hr) |
| KR (2) | KR20180008449A (hr) |
| CN (1) | CN107667119A (hr) |
| AU (2) | AU2016262074A1 (hr) |
| CA (1) | CA2983282A1 (hr) |
| DK (1) | DK3294770T4 (hr) |
| ES (1) | ES2835866T5 (hr) |
| FI (1) | FI3294770T4 (hr) |
| HK (1) | HK1250376A1 (hr) |
| HR (1) | HRP20201900T4 (hr) |
| HU (1) | HUE051815T2 (hr) |
| IL (2) | IL295002A (hr) |
| LT (1) | LT3294770T (hr) |
| MX (2) | MX2017014381A (hr) |
| PL (1) | PL3294770T5 (hr) |
| PT (1) | PT3294770T (hr) |
| RS (1) | RS61152B2 (hr) |
| SI (1) | SI3294770T2 (hr) |
| WO (1) | WO2016183326A1 (hr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3177292B1 (en) | 2014-08-07 | 2020-11-25 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| HRP20201900T4 (hr) | 2015-05-12 | 2024-06-07 | F. Hoffmann - La Roche Ag | Terapeutski i dijagnostički postupci kod raka |
| WO2017024032A2 (en) | 2015-08-03 | 2017-02-09 | Enb Therapeutics, Llc | Compositions and methods for treating cancers associated with etbr activation |
| PT3385395T (pt) * | 2015-08-17 | 2020-05-06 | Kura Oncology Inc | Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase |
| EP3400246B1 (en) | 2016-01-08 | 2020-10-21 | H. Hoffnabb-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| JP7235508B2 (ja) * | 2016-11-24 | 2023-03-08 | 第一三共株式会社 | Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法 |
| KR20190102059A (ko) * | 2017-01-07 | 2019-09-02 | 메르크 파텐트 게엠베하 | 표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태 |
| WO2018136553A1 (en) * | 2017-01-18 | 2018-07-26 | Genentech, Inc. | Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof |
| EP3494235A1 (en) * | 2017-02-17 | 2019-06-12 | Stichting VUmc | Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets |
| JP7324710B2 (ja) * | 2017-02-21 | 2023-08-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 肺癌の処置のための抗ｐｄ－１抗体 |
| WO2018160717A1 (en) * | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| EP3589754B1 (en) | 2017-03-01 | 2023-06-28 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| CA3069469A1 (en) | 2017-07-21 | 2019-01-24 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| US10269803B2 (en) * | 2017-08-31 | 2019-04-23 | Taiwan Semiconductor Manufacturing Company, Ltd. | Hybrid scheme for improved performance for P-type and N-type FinFETs |
| AU2019206652B2 (en) | 2018-01-12 | 2024-11-14 | Enb Therapeutics, Inc. | Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation |
| CA3091373A1 (en) * | 2018-02-17 | 2019-08-22 | Apollomics Inc. | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| WO2019207030A1 (en) * | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
| CN112771177A (zh) * | 2018-05-21 | 2021-05-07 | 纳米线科技公司 | 分子基因标签及其使用方法 |
| EP3823611A1 (en) * | 2018-07-18 | 2021-05-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
| KR102084196B1 (ko) * | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| AU2019342133B8 (en) | 2018-09-21 | 2025-08-07 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| AU2019361983A1 (en) | 2018-10-18 | 2021-05-20 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| JP2022530920A (ja) * | 2019-05-03 | 2022-07-04 | コーネル ユニバーシティー | 核酸配列の変異、発現、スプライスバリアント、転座、コピー数、またはメチル化変化を特定及び定量するためのマーカー |
| CN111973739B (zh) * | 2019-05-23 | 2024-02-13 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| CN112805566A (zh) * | 2019-07-29 | 2021-05-14 | 上海谷森医药有限公司 | 用于吸入治疗肺癌的抗体类药物制剂 |
| EP3792632A1 (en) * | 2019-09-16 | 2021-03-17 | Vito NV | Immunotherapy markers |
| TW202142230A (zh) | 2020-01-27 | 2021-11-16 | 美商建南德克公司 | 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法 |
| JP2023520515A (ja) * | 2020-04-03 | 2023-05-17 | ジェネンテック， インコーポレイテッド | がんに対する治療方法及び診断方法 |
| EP4147052A1 (en) * | 2020-05-05 | 2023-03-15 | F. Hoffmann-La Roche AG | Predicting response to pd-1 axis inhibitors |
| KR20230025691A (ko) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | 삼중 음성 유방암을 치료하기 위한 방법과 조성물 |
| JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック， インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
| US20240336693A1 (en) * | 2021-08-10 | 2024-10-10 | Apexigen, Inc. | Biomarkers for cd40 agonist therapy |
| CN119183377A (zh) | 2022-05-12 | 2024-12-24 | 基因泰克公司 | 包含shp2抑制剂和pd-l1结合拮抗剂的方法和组合物 |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| WO2024163009A1 (en) | 2023-01-31 | 2024-08-08 | Genentech, Inc. | Methods and compositions for treating urothelial bladder cancer |
| TW202436339A (zh) | 2023-01-31 | 2024-09-16 | 瑞士商赫孚孟拉羅股份公司 | 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途 |
| AU2024230918A1 (en) | 2023-03-06 | 2025-10-16 | Genentech, Inc. | Prognostic and therapeutic methods for non-small cell lung cancer |
| WO2025049277A1 (en) | 2023-08-25 | 2025-03-06 | Genentech, Inc. | Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| PT659439E (pt) | 1993-12-24 | 2002-04-29 | Merck Patent Gmbh | Imunoconjugados |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP2163546B1 (en) | 1995-03-30 | 2016-06-01 | Pfizer Products Inc. | Quinazoline derivatives |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| TR199800012T1 (xx) | 1995-07-06 | 1998-04-21 | Novartis Ag | Piroloprimidinler ve preparasyon i�in tatbikler. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| DE69710712T3 (de) | 1996-04-12 | 2010-12-23 | Warner-Lambert Co. Llc | Umkehrbare inhibitoren von tyrosin kinasen |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| JP3687900B2 (ja) | 1998-11-19 | 2005-08-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | チロシンキナーゼの不可逆的阻害剤であるｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）キナゾリン−６−イル］アクリルアミド |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
| ES2601882T5 (es) | 1999-04-09 | 2021-06-07 | Kyowa Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| DK1242438T3 (da) | 1999-12-29 | 2007-02-12 | Immunogen Inc | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse |
| DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1916303B1 (en) | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| CA2481656A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK2289936T3 (en) | 2002-12-16 | 2017-07-31 | Genentech Inc | IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF |
| EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
| WO2005035778A1 (ja) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
| DK2380910T3 (en) | 2003-11-05 | 2015-10-19 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| PT2489364E (pt) | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| US8219149B2 (en) | 2005-06-29 | 2012-07-10 | Nokia Corporation | Mobile communication terminal |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| HUE034465T2 (en) | 2008-02-11 | 2018-02-28 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2328919A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| EP4331604B9 (en) * | 2008-12-09 | 2025-07-23 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
| SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| AU2014235453A1 (en) | 2013-03-15 | 2015-10-08 | Genentech, Inc. | Biomarkers and methods of treating PD-1 and PD-L1 related conditions |
| EP3293275B1 (en) * | 2013-06-06 | 2021-08-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| IL292193B2 (en) | 2013-09-11 | 2024-11-01 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| PT3508502T (pt) | 2013-09-20 | 2023-06-22 | Bristol Myers Squibb Co | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores |
| WO2016034718A1 (en) | 2014-09-05 | 2016-03-10 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma) |
| EP3254110B1 (en) * | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| HRP20201900T4 (hr) | 2015-05-12 | 2024-06-07 | F. Hoffmann - La Roche Ag | Terapeutski i dijagnostički postupci kod raka |
| JP2023523450A (ja) * | 2020-04-28 | 2023-06-05 | ジェネンテック， インコーポレイテッド | 非小細胞肺がん免疫療法のための方法及び組成物 |
-
2016
- 2016-05-12 HR HRP20201900TT patent/HRP20201900T4/hr unknown
- 2016-05-12 DK DK16724821.0T patent/DK3294770T4/da active
- 2016-05-12 KR KR1020177031945A patent/KR20180008449A/ko not_active Ceased
- 2016-05-12 WO PCT/US2016/032112 patent/WO2016183326A1/en not_active Ceased
- 2016-05-12 MX MX2017014381A patent/MX2017014381A/es unknown
- 2016-05-12 AU AU2016262074A patent/AU2016262074A1/en not_active Abandoned
- 2016-05-12 FI FIEP16724821.0T patent/FI3294770T4/fi active
- 2016-05-12 JP JP2017558454A patent/JP7048319B2/ja active Active
- 2016-05-12 EP EP16724821.0A patent/EP3294770B2/en active Active
- 2016-05-12 CN CN201680031772.9A patent/CN107667119A/zh active Pending
- 2016-05-12 SI SI201631013T patent/SI3294770T2/sl unknown
- 2016-05-12 KR KR1020257003019A patent/KR20250021621A/ko active Pending
- 2016-05-12 RS RS20201469A patent/RS61152B2/sr unknown
- 2016-05-12 HU HUE16724821A patent/HUE051815T2/hu unknown
- 2016-05-12 ES ES16724821T patent/ES2835866T5/es active Active
- 2016-05-12 IL IL295002A patent/IL295002A/en unknown
- 2016-05-12 HK HK18109832.3A patent/HK1250376A1/zh unknown
- 2016-05-12 IL IL255312A patent/IL255312B/en unknown
- 2016-05-12 PT PT167248210T patent/PT3294770T/pt unknown
- 2016-05-12 CA CA2983282A patent/CA2983282A1/en active Pending
- 2016-05-12 LT LTEP16724821.0T patent/LT3294770T/lt unknown
- 2016-05-12 PL PL16724821.0T patent/PL3294770T5/pl unknown
- 2016-05-12 EP EP20191243.3A patent/EP3783029A1/en active Pending
-
2017
- 2017-10-19 US US15/787,988 patent/US20180030138A1/en not_active Abandoned
- 2017-11-09 MX MX2023002251A patent/MX2023002251A/es unknown
-
2021
- 2021-11-26 US US17/535,898 patent/US20220073623A1/en active Pending
-
2022
- 2022-02-01 JP JP2022013871A patent/JP7534344B2/ja active Active
- 2022-05-24 AU AU2022203501A patent/AU2022203501B2/en active Active
-
2024
- 2024-08-01 JP JP2024125652A patent/JP2024170394A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201900T4 (hr) | Terapeutski i dijagnostički postupci kod raka | |
| Ilié et al. | Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer | |
| Kim et al. | Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers | |
| Moehler et al. | Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study | |
| Martin et al. | Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer | |
| Cocks et al. | Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort | |
| Halama et al. | Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy | |
| Lantuejoul et al. | Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma | |
| Choueiri et al. | PD-L1 expression in nonclear-cell renal cell carcinoma | |
| Linger et al. | Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors | |
| Walter et al. | PD‐L1 expression in extrahepatic cholangiocarcinoma | |
| Toda et al. | PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions | |
| Groen et al. | A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) | |
| JP2019524887A5 (hr) | ||
| Bačić et al. | Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA) | |
| Letelier et al. | Immunohistochemical expression of vascular endothelial growth factor A in advanced gallbladder carcinoma | |
| Hisamatsu et al. | Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer | |
| Husain et al. | How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study | |
| De-Colle et al. | SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy | |
| Ha et al. | Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma | |
| Sterlacci et al. | Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung | |
| Iida et al. | Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma | |
| Hadebe et al. | Current status of 68Ga-Pentixafor in solid tumours | |
| PH12021552622A1 (en) | Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors | |
| Miki et al. | Tumor-associated macrophages in the development of 4-nitroquinoline-1-oxide-induced tongue squamous cell carcinoma in a mouse model |